These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21746752)

  • 1. Amisulpride-induced acute akathisia in OCD: an example of dysfunctional dopamine-serotonin interactions?
    Ersche KD; Cumming P; Craig KJ; Müller U; Fineberg NA; Bullmore ET; Robbins TW
    J Psychopharmacol; 2012 Jun; 26(6):887-90. PubMed ID: 21746752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amisulpride as add-on treatment for resistant obsessive-compulsive disorder: retrospective case series.
    Miodownik C; Bergman J; Lerner PP; Kreinin A; Lerner V
    Clin Neuropharmacol; 2015; 38(1):26-9. PubMed ID: 25580923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial.
    Metin O; Yazici K; Tot S; Yazici AE
    Hum Psychopharmacol; 2003 Aug; 18(6):463-7. PubMed ID: 12923825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperpigmentation with amisulpride.
    Mendhekar DN
    Aust N Z J Psychiatry; 2009 Jan; 43(1):88. PubMed ID: 19086350
    [No Abstract]   [Full Text] [Related]  

  • 5. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
    Saxena S; Wang D; Bystritsky A; Baxter LR
    J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effect of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient.
    Poyurovsky M; Meerovich I; Weizman A
    Int Clin Psychopharmacol; 1995 Jun; 10(2):111-4. PubMed ID: 7673653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
    Wolmarans de W; Brand L; Stein DJ; Harvey BH
    Behav Brain Res; 2013 Nov; 256():545-53. PubMed ID: 24013013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of obsessive-compulsive disorder: a literature review.
    Lochner C; Stein DJ
    Harv Rev Psychiatry; 2003; 11(3):113-32. PubMed ID: 12893502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obsessive compulsive disorder: serotonin and beyond.
    Zohar J; Chopra M; Sasson Y; Amiaz R; Amital D
    World J Biol Psychiatry; 2000 Apr; 1(2):92-100. PubMed ID: 12607204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
    Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].
    Okamoto Y
    Seishin Shinkeigaku Zasshi; 2011; 113(1):36-44. PubMed ID: 21404630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
    Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
    J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder.
    Goddard AW; Shekhar A; Whiteman AF; McDougle CJ
    Drug Discov Today; 2008 Apr; 13(7-8):325-32. PubMed ID: 18405845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system].
    Baving L; Schmidt MH
    Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):35-44. PubMed ID: 10746297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between obsessive-compulsive disorder and chaos.
    Kubota S; Sakai K
    Med Hypotheses; 2002 Jul; 59(1):16-23. PubMed ID: 12160676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional connectivity of the raphe nucleus as a predictor of the response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Kim M; Kwak S; Yoon YB; Kwak YB; Kim T; Cho KIK; Lee TY; Kwon JS
    Neuropsychopharmacology; 2019 Nov; 44(12):2073-2081. PubMed ID: 31189178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.